№ 01
Best Overall
NexLife
Highest aggregate score across pricing transparency, pharmacy sourcing disclosure, and clinical oversight — the three pillars weighted heaviest in our methodology.
Read review →A methodology-driven look at sixteen providers prescribing semaglutide, tirzepatide, and oral GLP-1s — graded on pricing transparency, pharmacy sourcing, clinical oversight, and patient experience.
Best value for first-timers — flat-rate pricing across all doses, free expedited shipping, and a single bundled monthly fee that covers consultation, medication, and delivery. No subscription lock-in.
Eight categories, eight winners — scored against our 14-point methodology.
Highest aggregate score across pricing transparency, pharmacy sourcing disclosure, and clinical oversight — the three pillars weighted heaviest in our methodology.
Read review →Compounded semaglutide at $165/month and tirzepatide at $215/month — flat-rate, with consultation, medication, and free expedited shipping bundled into a single monthly fee. No subscription lock-in.1
Read review →The only program we reviewed that explicitly names its pharmacy classification (U.S.-licensed 503A) and discloses third-party USP <85> testing on its patient-facing site.1
Read review →Unlimited physician access plus registered-dietitian support included at the membership tier — the most clinical contact-time per dollar in our review.
Compare pricing →Detailed published medical-team documentation and an all-inclusive model that bundles physician visits, supplies, and shipping into a single rate.
Compare pricing →Publishes "same price at every dose" prominently across product pages — predictable monthly cost as patients titrate up.
Compare pricing →Documented coverage across all 50 states with consistent pricing, plus oral and injectable options under a single program.
Compare pricing →Lowest-friction onboarding flow, recognizable brand, and the clearest first-month vs. ongoing-rate disclosure of any direct-to-consumer program.
Compare pricing →Every provider in our review is evaluated against the same 14-point rubric, weighted toward the dimensions that matter most for patient outcomes and financial protection.
Read full methodology →Flat-rate vs. titration-based pricing, hidden fees, intro-rate clarity, total annual cost.
25% weight503A or 503B disclosure, USP testing standards, batch quality control documentation.
25% weightMD/DO involvement, NP/PA roles, intake review depth, medical-necessity documentation.
20% weightOnboarding clarity, ongoing support access, side-effect management, cancellation terms.
15% weightState availability, HSA/FSA acceptance, eligibility breadth, BMI threshold transparency.
15% weightHealth journalists, a licensed pharmacist, and a U.S.-licensed physician reviewer.
Amanda covers telehealth and digital health access. Eight years in health journalism. Leads editorial direction at GLP Agonists.
Dr. Kennah is a U.S.-licensed physician who reviews medication and dosing content for clinical accuracy and oversees editorial coverage on prescription topics.
Licensed pharmacist with twelve years in clinical pharmacy, focused on cardiometabolic and endocrine medications.
Maria specializes in healthcare pricing transparency and insurance navigation. Researches and fact-checks all provider pricing.